A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an innovative laparoscopic intraperitoneal chemotherapy approach with the advantage of a deeper tissue penetration. Thus far, oxaliplatin has been administered at an arbitrary dose of 92 mg/m<sup>2</sup>, cisplatin at 7.5 mg/m&l...
Main Authors: | Manuela Robella, Michele De Simone, Paola Berchialla, Monica Argenziano, Alice Borsano, Shoeb Ansari, Ornella Abollino, Eleonora Ficiarà, Armando Cinquegrana, Roberta Cavalli, Marco Vaira |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/5/1060 |
Similar Items
-
Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx®) as Pressurized Intraperitoneal Aerosol Chemotherapy
by: Manuela Robella, et al.
Published: (2019-06-01) -
Study Protocol: Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Metastases
by: Manuela Robella, et al.
Published: (2021-05-01) -
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
by: Michele De Simone, et al.
Published: (2020-04-01) -
Pressurized intra-peritoneal aerosol chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model
by: Myriam Mimouni, et al.
Published: (2021-04-01) -
Pressurized intraperitoneal aerosol chemotherapy in nonresectable carcinomatosis from colorectal cancer
by: Nicolae BACALBASA, et al.
Published: (2021-06-01)